Press release
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
INPEFA® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"INPEFA® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) Expect Topline Data in Q2 2025 from PROGRESS Phase 2b Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2024 and provided an update on key corporate milestones. “This past quarter has resulted in important progress for the company,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “We believe our novel set of commercial and pipeline opportunities, derived from our unique genomics target discovery platform Genome5000, have the potential to transform our company and significantly improve the healthcare treatment landscape in their respective therapeutic areas. Entering the second half of 2024, our first and most important priority will be closely evaluating our business strategy, resources and goals to ensure we are optimally positioned to promote the long-term success and growth of Lexicon,” continued Dr. Exton. Second Quarter 2024 Pipeline Highlights INPEFA (sotagliflozin) for Heart Failure The INPEFA launch in heart failure continues to progress and market access discussions remain ongoing. Net sales for the quarter were $1.6 million. ZYNQUISTA (sotagliflozin) for Type 1 Diabetes Lexicon resubmitted its NDA for ZYNQUISTA as an adjunct to insulin in adults with type 1 diabetes and CKD on June 20, 2024. FDA notified the company that it considers the resubmission to be a complete response to its 2019 action letter regarding the NDA and provided a PDUFA goal date of December 20, 2024. Preparations are underway for an early 2025 launch. Sotagliflozin for HCM Lexicon has commenced the SONATA Phase 3 study of sotagliflozin in HCM, with multiple sites open for recruitment. LX9211 for DPNP Patient enrollment remains on track in the PROGRESS Phase 2b dose optimization study of LX9211 in DPNP. LX9211 has the potential to become the first non-opioid drug therapy approved in neuropathic pain in more than 20 ...